Solventum (NYSE:SOLV) Coverage Initiated at Rothschild & Co Redburn

Analysts at Rothschild & Co Redburn assumed coverage on shares of Solventum (NYSE:SOLV) in a report released on Tuesday,Benzinga reports. The brokerage set a “sell” rating and a $60.00 price target on the stock. Rothschild & Co Redburn’s target price would indicate a potential downside of 8.73% from the company’s previous close.

Other analysts have also recently issued reports about the stock. Mizuho set a $100.00 price objective on shares of Solventum and gave the company an “outperform” rating in a research note on Tuesday, January 20th. Wall Street Zen lowered shares of Solventum from a “buy” rating to a “hold” rating in a research note on Sunday, March 8th. KeyCorp raised their target price on shares of Solventum from $97.00 to $99.00 and gave the stock an “overweight” rating in a report on Friday, February 27th. Piper Sandler restated an “overweight” rating on shares of Solventum in a research report on Wednesday, December 17th. Finally, BTIG Research reaffirmed a “buy” rating and issued a $100.00 price target on shares of Solventum in a report on Friday, February 27th. Seven investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $90.64.

Solventum Stock Down 0.1%

Shares of SOLV stock opened at $65.74 on Tuesday. The stock’s 50-day simple moving average is $74.32 and its 200-day simple moving average is $75.78. The company has a debt-to-equity ratio of 1.00, a quick ratio of 0.89 and a current ratio of 1.23. The firm has a market capitalization of $11.41 billion, a PE ratio of 7.41, a P/E/G ratio of 1.08 and a beta of 0.40. Solventum has a fifty-two week low of $60.70 and a fifty-two week high of $88.20.

Solventum (NYSE:SOLV) last released its earnings results on Thursday, February 26th. The company reported $1.57 EPS for the quarter, topping analysts’ consensus estimates of $1.50 by $0.07. The firm had revenue of $2 billion during the quarter, compared to the consensus estimate of $1.96 billion. Solventum had a return on equity of 25.26% and a net margin of 18.69%.The company’s revenue was down 3.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.41 earnings per share. Solventum has set its FY 2026 guidance at 6.400-6.600 EPS. Equities analysts expect that Solventum will post 6.58 earnings per share for the current year.

Insider Activity

In other Solventum news, Director Amy Mcbride Wendell bought 1,475 shares of the firm’s stock in a transaction dated Tuesday, March 10th. The shares were purchased at an average price of $68.03 per share, for a total transaction of $100,344.25. Following the transaction, the director directly owned 5,039 shares of the company’s stock, valued at approximately $342,803.17. This represents a 41.39% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 0.05% of the stock is owned by company insiders.

Hedge Funds Weigh In On Solventum

Large investors have recently added to or reduced their stakes in the stock. Hilltop National Bank grew its position in shares of Solventum by 71.3% in the fourth quarter. Hilltop National Bank now owns 310 shares of the company’s stock valued at $25,000 after purchasing an additional 129 shares during the period. CrossGen Wealth LLC acquired a new position in shares of Solventum during the 4th quarter worth about $25,000. Measured Wealth Private Client Group LLC acquired a new position in shares of Solventum during the 3rd quarter worth about $25,000. Deseret Mutual Benefit Administrators lifted its stake in Solventum by 78.7% in the 3rd quarter. Deseret Mutual Benefit Administrators now owns 370 shares of the company’s stock valued at $27,000 after buying an additional 163 shares in the last quarter. Finally, JNBA Financial Advisors lifted its stake in Solventum by 205.4% in the 4th quarter. JNBA Financial Advisors now owns 339 shares of the company’s stock valued at $27,000 after buying an additional 228 shares in the last quarter.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.